Black Diamond Therapeutics Prepares to Release Phase 2 Data for Silevertinib in EGFR-Mutant NSCLC
Key Insights
Black Diamond Therapeutics plans to disclose objective response rate and preliminary duration of treatment data from 43 patients in its Phase 2 trial of silevertinib (search) for frontline non-classical EGFR (search)-mutant NSCLC later this quarter.
The company reported $135.5 million in cash reserves as of September 30, 2025, sufficient to fund operations into Q4 2027, while reducing R&D expenses by 43% year-over-year to $7.4 million.
Progression-free survival data is expected in the first half of 2026, when the company intends to seek FDA feedback on a potential registrational pathway for frontline EGFR (search)-mutant NSCLC.
Black Diamond Therapeutics is poised to release critical Phase 2 efficacy data for silevertinib (search), its brain-penetrant fourth-generation EGFR (search) inhibitor, in patients with non-classical EGFR-mutant non-small cell lung cancer (NSCLC). The clinical-stage oncology company announced it will disclose objective response rate (ORR) and preliminary duration of treatment data from all 43 patients enrolled in the frontline NSCLC trial later this quarter.
"We are looking forward to sharing a clinical update later this quarter from our silevertinib (search) Phase 2 trial in newly diagnosed patients with EGFRm NSCLC," said Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. "The update will include ORR and preliminary duration of treatment data, while PFS data is expected in the first half of 2026."
Clinical Development Progress
The upcoming data release represents a significant milestone for silevertinib (search)'s development in frontline treatment of NSCLC patients with non-classical epidermal growth factor receptor (EGFR (search)) mutations. Black Diamond plans to seek U.S. Food and Drug Administration (FDA) feedback on a potential registrational pathway in frontline EGFR-mutant NSCLC during the first half of 2026, when progression-free survival (PFS) data from the ongoing Phase 2 trial becomes available.
The company is actively exploring partnership opportunities in both NSCLC and glioblastoma (GBM) to advance silevertinib (search) into pivotal development. Silevertinib is designed as part of Black Diamond's MasterKey therapy platform, which targets families of oncogenic mutations and is engineered to address genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and achieve brain penetration for central nervous system disease treatment.
Financial Position and Operational Efficiency
Black Diamond reported a strengthened financial position with approximately $135.5 million in cash, cash equivalents, and investments as of September 30, 2025, compared to $98.6 million at the end of 2024. The company projects this funding will be sufficient to support operations into the fourth quarter of 2027.
The company demonstrated improved operational efficiency with research and development expenses decreasing to $7.4 million in Q3 2025 from $12.9 million in the same period of 2024. This 43% reduction was primarily attributed to workforce efficiencies and the outlicensing of BDTX-4933, allowing increased focus on silevertinib (search) development.
General and administrative expenses also declined to $3.5 million from $5.2 million year-over-year, primarily due to restructuring initiatives announced in October 2024. Net cash used in operations improved to $7.9 million in Q3 2025 compared to $11.3 million in Q3 2024.
Strategic Focus on EGFR-Targeted Therapy
Black Diamond's MasterKey approach with silevertinib (search) addresses the unmet medical need for newly diagnosed NSCLC patients with non-classical EGFR (search) mutations. The fourth-generation EGFR inhibitor is designed to overcome resistance mechanisms that limit current therapies while maintaining brain penetration capabilities for treating central nervous system metastases.
The company's net loss for the third quarter of 2025 was $8.5 million, representing a significant improvement from the $15.6 million net loss reported in the same period of 2024. This financial improvement reflects the company's strategic focus on advancing silevertinib (search) while maintaining operational discipline.